Cargando…
Author Correction: (18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
Autores principales: | Hsu, Jung-Lung, Chen, Shih-Hsin, Hsiao, Ing-Tsung, Lu, Chin-Song, Yen, Tzu-Chen, Okamura, Nobuyuki, Lin, Kun-Ju, Weng, Yi-Hsin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873254/ https://www.ncbi.nlm.nih.gov/pubmed/33564024 http://dx.doi.org/10.1038/s41598-021-83535-z |
Ejemplares similares
-
(18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2020) -
Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018) -
[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2018) -
Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018) -
Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)